Letter to the Editor Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia.

Presents letters to the editors related to the dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukemia. Principal mechanisms by which resistance to imatinib can develop; Indication on the increase of imatinib in chronic myelogenous leukemia; Inclusion of the complete hemtologic, cytogenetic and molecular remission with standard induction therapy.